Filing Details

Accession Number:
0000874015-18-000018
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-01-17 21:22:14
Reporting Period:
2018-01-15
Accepted Time:
2018-01-17 21:22:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874015 Ionis Pharmaceuticals Inc IONS Pharmaceutical Preparations (2834) 330336973
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
897667 T Stanley Crooke C/O Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad CA 92010
Chairman And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-01-15 29,612 $0.00 67,626 No 4 M Direct
Common Stock Disposition 2018-01-15 15,893 $51.76 51,733 No 4 S Direct
Common Stock Acquisiton 2018-01-15 1,722 $0.00 4,784 No 4 M Indirect By wife
Common Stock Disposition 2018-01-15 656 $51.76 4,128 No 4 S Indirect By wife
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Indirect By wife
No 4 S Indirect By wife
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Acquisiton 2018-01-15 35,149 $0.00 35,149 $0.00
Common Stock Restricted Stock Units Acquisiton 2018-01-15 3,911 $0.00 3,911 $0.00
Common Stock Restricted Stock Units Disposition 2018-01-15 29,612 $0.00 29,612 $0.00
Common Stock Restricted Stock Units Disposition 2018-01-15 1,722 $0.00 1,722 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
35,149 No 4 A Direct
3,911 No 4 A Indirect
43,515 No 4 M Direct
3,047 No 4 M Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 725,391 Indirect By trust
Footnotes
  1. Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards.
  2. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.759 to $51.768, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
  4. Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.
  5. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
  6. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
  7. Grant to reporting person's wife of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan.